默沙东（Merck）已达成协议，将全资收购生物制药企业Terns Pharmaceuticals, Inc.。此次战略收购的核心标的，是Terns公司旗下处于研发阶段的创新药物Tern-701。该药物是一款针对慢性髓性白血病（CML）的新型候选疗法，其加入将显著拓宽并增强默沙东在血液疾病领域的研发管线。
通过此次收购，默沙东旨在巩固其在肿瘤治疗领域的领先地位，并为慢性髓性白血病患者带来新的治疗希望。
默沙东（Merck）已达成协议，将全资收购生物制药企业Terns Pharmaceuticals, Inc.。此次战略收购的核心标的，是Terns公司旗下处于研发阶段的创新药物Tern-701。该药物是一款针对慢性髓性白血病（CML）的新型候选疗法，其加入将显著拓宽并增强默沙东在血液疾病领域的研发管线。
通过此次收购，默沙东旨在巩固其在肿瘤治疗领域的领先地位，并为慢性髓性白血病患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.